Cargando…
Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting 1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population protection. This study aims to estimate the economic impact of a range o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639502/ https://www.ncbi.nlm.nih.gov/pubmed/26553677 http://dx.doi.org/10.1093/cid/civ600 |
_version_ | 1782399924585889792 |
---|---|
author | Colombini, Anaïs Trotter, Caroline Madrid, Yvette Karachaliou, Andromachi Preziosi, Marie-Pierre |
author_facet | Colombini, Anaïs Trotter, Caroline Madrid, Yvette Karachaliou, Andromachi Preziosi, Marie-Pierre |
author_sort | Colombini, Anaïs |
collection | PubMed |
description | Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting 1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population protection. This study aims to estimate the economic impact of a range of vaccination strategies in Burkina Faso. Methods. We performed a cost-of-illness study, comparing different vaccination scenarios in terms of costs to both households and health systems over a 26-year time horizon. These scenarios are (1) reactive vaccination campaign (baseline comparator); (2) preventive vaccination campaign; (3) routine immunization at 9 months; and (4) a combination of routine and an initial catchup campaign of children under 5. Costs were estimated from a literature review, which included unpublished programmatic documents and peer-reviewed publications. The future disease burden for each vaccination strategy was predicted using a dynamic transmission model of group A Neisseria meningitidis. Results. From 2010 to 2014, the total costs associated with the preventive campaign targeting 1- to 29-year-olds with MenAfriVac were similar to the estimated costs of the reactive vaccination strategy (approximately 10 million US dollars [USD]). Between 2015 and 2035, routine immunization with or without a catch-up campaign of 1- to 4-year-olds is cost saving compared with the reactive strategy, both with and without discounting costs and cases. Most of the savings are accrued from lower costs of case management and household costs resulting from a lower burden of disease. After the initial investment in the preventive strategy, 1 USD invested in the routine strategy saves an additional 1.3 USD compared to the reactive strategy. Conclusions. Prevention strategies using MenAfriVac will be significantly cost saving in Burkina Faso, both for the health system and for households, compared with the reactive strategy. This will protect households from catastrophic expenditures and increase the development capacity of the population. |
format | Online Article Text |
id | pubmed-4639502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46395022015-11-12 Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso Colombini, Anaïs Trotter, Caroline Madrid, Yvette Karachaliou, Andromachi Preziosi, Marie-Pierre Clin Infect Dis The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting 1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population protection. This study aims to estimate the economic impact of a range of vaccination strategies in Burkina Faso. Methods. We performed a cost-of-illness study, comparing different vaccination scenarios in terms of costs to both households and health systems over a 26-year time horizon. These scenarios are (1) reactive vaccination campaign (baseline comparator); (2) preventive vaccination campaign; (3) routine immunization at 9 months; and (4) a combination of routine and an initial catchup campaign of children under 5. Costs were estimated from a literature review, which included unpublished programmatic documents and peer-reviewed publications. The future disease burden for each vaccination strategy was predicted using a dynamic transmission model of group A Neisseria meningitidis. Results. From 2010 to 2014, the total costs associated with the preventive campaign targeting 1- to 29-year-olds with MenAfriVac were similar to the estimated costs of the reactive vaccination strategy (approximately 10 million US dollars [USD]). Between 2015 and 2035, routine immunization with or without a catch-up campaign of 1- to 4-year-olds is cost saving compared with the reactive strategy, both with and without discounting costs and cases. Most of the savings are accrued from lower costs of case management and household costs resulting from a lower burden of disease. After the initial investment in the preventive strategy, 1 USD invested in the routine strategy saves an additional 1.3 USD compared to the reactive strategy. Conclusions. Prevention strategies using MenAfriVac will be significantly cost saving in Burkina Faso, both for the health system and for households, compared with the reactive strategy. This will protect households from catastrophic expenditures and increase the development capacity of the population. Oxford University Press 2015-11-15 2015-11-09 /pmc/articles/PMC4639502/ /pubmed/26553677 http://dx.doi.org/10.1093/cid/civ600 Text en © 2015 World Health Organization; licensee Oxford Journals. http://creativecommons.org/licenses/by/3.0/igo/legalcode This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL |
spellingShingle | The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Colombini, Anaïs Trotter, Caroline Madrid, Yvette Karachaliou, Andromachi Preziosi, Marie-Pierre Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso |
title | Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso |
title_full | Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso |
title_fullStr | Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso |
title_full_unstemmed | Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso |
title_short | Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso |
title_sort | costs of neisseria meningitidis group a disease and economic impact of vaccination in burkina faso |
topic | The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639502/ https://www.ncbi.nlm.nih.gov/pubmed/26553677 http://dx.doi.org/10.1093/cid/civ600 |
work_keys_str_mv | AT colombinianais costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso AT trottercaroline costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso AT madridyvette costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso AT karachaliouandromachi costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso AT preziosimariepierre costsofneisseriameningitidisgroupadiseaseandeconomicimpactofvaccinationinburkinafaso |